A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study

Emmanouil Mentzakis, Patricia Stefanowska, Jeremiah Hurley

Research output: Contribution to journalArticle

51 Citations (Scopus)


Policy debate about funding criteria for drugs used to treat rare, orphan diseases is gaining prominence. This study presents evidence from a discrete choice experiment using a convenience sample of university students to investigate individual preferences regarding public funding for drugs used to treat rare diseases and common diseases. This pilot study finds that: other things equal, the respondents do not prefer to have the government spend more for drugs used to treat rare diseases; that respondents are not willing to pay more per life year gained for a rare disease than a common disease; and that respondents weigh relevant attributes of the coverage decisions (e.g. costs, disease severity and treatment effectiveness) similarly for both rare and common diseases. The results confirm the importance of severity and treatment effectiveness in preferences for public funding. Although this is the first study of its kind, the results send a cautionary message regarding the special treatment of orphan drugs in coverage decision-making.
Original languageEnglish
Pages (from-to)405-433
Number of pages29
JournalHealth Economics, Policy and Law
Publication statusPublished - 2010

Cite this